Erythrocyte sodium-lithium countertransport is not different in type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy.
We studied erythrocyte sodium-lithium countertransport in 33 patients with Type 1 (insulin-dependent) diabetes mellitus with diabetic nephropathy, 18 patients with Type 1 diabetes without diabetic nephropathy and in 42 non-diabetic patients with various other renal diseases. No significant differences were found in sodium-lithium countertransport between these three groups (median (range) 322 (162-676) vs 321 (189-627) vs 300 (142-655) mumol.l cells-1.h-1). We conclude, that sodium-lithium countertransport cannot be used as a marker for diabetic nephropathy.
Elving
L D
LD
Department of Medicine, University Hospital, Nijmegen, The Netherlands.
Wetzels
J F
JF
de Nobel
E
E
Berden
J H
JH
D000328:Adult; D017920:Antiporters; D002352:Carrier Proteins / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000097:blood*; D004912:Erythrocytes / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D008875:Middle Aged; D012016:Reference Values
D017920:Antiporters; D002352:Carrier Proteins; D006442:Glycated Hemoglobin; C045885:sodium-lithium countertransporter